



## The 45<sup>th</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards

© Springer Nature Limited 2019

24–27 March 2019 ● Frankfurt, Germany

Modified and published with permission from <https://www.ebmt.org/annual-meeting>

**Sponsorship Statement:** Publication of this supplement is sponsored by the European Society for Blood and Marrow Transplantation. All content was reviewed and approved by the EBMT Committee, which held full responsibility for the abstract selections.

**1998**

**Induction of alloantigen specific anergy does not impair cytolytic activity of leukaemia reactive human T-cells**

P. Comolie, F. Locatelli, D. Montagna, V. Calcaterra, A. Moretta, G. Giorgiani, F. Bonetti, M. Zecca, R. Maccario (Pavia, I)

**1999**

**First results of the autologous transplantation after serum-free retroviral gene marking of chemotherapy mobilised PBSC in chronic myeloid leukaemia**

C. von Kalle, H. Glimm, S. Klingenberg, M. Schmidt, C. Waller, M. Engelhard, K. Flügge, G. Pache, C. Philbrook, T. Vraetz, J. Finke, R. Mertelsmann, W. Lange (Freiburg, D)

**2000**

**Current results in haploidentical stem cell transplantation in children**

T.E. Klingebiel, P. Lang, M. Schumm, P. Bader, P.G. Schlegel, M. Eyrich, J. Greil, D. Niethammer, R. Handgretinger (Tübingen, Erlangen, D)

**2001**

**Generation of allo-HLA restricted minor histocompatibility antigen HA-1 specific cytotoxic T-cells (CTLs) as**

**tools for treatment of relapsed leukemia following HLA-mismatched stem cell transplantation**

T. Mutis, E. Blokland, E. Schrama, E. Goulmy (Leiden, NL)

**2002**

**Striking survival advantage of bad-risk acute myeloid leukaemia patients transplanted from haploidentical donors with KIR epitope incompatibility in the GVH direction**

L. Ruggeri, M. Capanni, E. Urbani, A. Tosti, K. Perruccio, S. Posati, F. Aversa, A. Tabilio, M.F. Martelli, A. Velardi (Perugia, I)

**2003**

**Differences in dendritic cell response to *Aspergillus fumigatus* as detected by gene expression profiling**

H. Einsele, H. Hebart, C. Sinzger, S. Riegler, M. Bonin, J. Loeffler (Tübingen, D)

**2004**

**NOD2/CARD15 mutations of recipients and donors associate with GvHD and TRM following allogeneic stem cell transplantation - results in 2 independent cohorts of patients**

E. Holler, G. Rogler, J. Brenmoehl, A. Dickinson, G. Jackson, H. Greinix, G. Fischer, H. Herfarth, J. Hahn, G. Eissner, J. Schölmerich, R. Andreesen (Regensburg, D; Newcastle, UK; Vienna, A)

## 2005

### **Clinical trials of immuno-gene therapy using tumour mRNA transfected dendritic cells**

G. Gaudernack, S. Aamdal, S. Dueland, J. Kyte, L. Mu, S. Saeboe-Larssen, M. Hauser, H. Waehre, G. Kvalheim (Oslo, N)

## 2006

### **Allogeneic SCT planned in CR-1 after intensive chemotherapy in patients with bad prognosis MDS results in better outcome in the intermediate/high-risk cytogenetic group: a study by the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups**

T. de Witte, A. Hagemeijer, S. Suci, A. Belhabri, M. Delforge, C. Aul, M. Aivado, D. Selleslag, H. Schouten, A. Ferrant, H. Biersack, S. Amadori, P. Muus, U. Jehn, F. Beeldens, J. Jansen, E. Hellstrom-Lindberg, T. Kovacs, U. Hess, P. Wijermans, G. Ossenkoppele, A. Gratwohl, J.-P. Marie, R. Willemze (Nijmegen, NL; Leuven, Brussels, B; Lyon, F; Duisburg, Düsseldorf, D; Brugge, B; Maastricht, NL; Essen, D; Rome, I; Munich, D; Stockholm, S; Lausanne, St. Gallen, CH; The Hague, Amsterdam, NL; Basel, CH; Paris, F; Leiden, NL)

### **Mesenchymal stem cells for treatment of severe acute and extensive chronic graft-versus-host disease**

O. Ringden, F. Frassoni, M. Uzunel, E. Lanino, B. Sundberg, H. Lonnies, G. Dini, A. Bacigalupo, F. Locatelli, W. Fibbe, K. Le Blanc (Stockholm, S; Genoa, I; Pavia, I; Leiden, NL)

## 2007

### **Single nucleotide polymorphisms of the NOD2/CARD15 gene are associated with significant increases in disease relapse and death in recipients of an unrelated donor haematopoietic stem cell transplant for acute leukaemia**

N. Mayor, B. Shaw, D. Hughes, H. Maldonado-Torres, J.A. Madrigal, S. Keshav, S.G.E. Marsh (London, UK)

## 2008

### **Inhibitory KIR-ligand mismatching is associated with decreased incidence of relapse and improved disease-free survival after unrelated cord blood stem cell transplantation for patients with acute leukaemia**

R. Willemze\*, C. Arrais Rodrigues, M. Labopin, I. Ionescu, K. Boudjedir, G. Sanz, G. Michel, G. Socié, B. Rio, J. Garcia, G. Kögler, L. Lecchi, P. Loiseau, E. Gluckman, V. Rocha on behalf of Eurocord-Netcord\* and Acute Leukaemia Working Party of the EBMT, Paris

## 2009

### **Prophylactic transfer of Bcr/Abl, PR1 and WT1-reactive donor T-cells after T-depleted allogeneic haematopoietic cell transplantation in patients with chronic myeloid leukaemia**

M. Bornhäuser, C. Thiede, A. Kiani, U. Platzbecker, U. Oelschlägel, J. Radke, J. Schetelig, D. Lehmann, K. Hölig, G. Ehniger, M. Schmitz (Dresden, DE)

## 2010

### **Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multi-centre study**

S. Corbacioglu, S. Cesaro, M. Faraci, D. Valteau-Couanet, B. Gruhn, J. Boelens, C. Uderzo, N. Hewitt, A. Rovelli, J. Schrum, I. Müller, A. Schulz, J. Stein, R. Wynn, J. Greil, S. Matthes, K. Sykora, M. Albert, A. O'Meara, J. Massaro, R. D'Agostino, M. Pfitzenmaier, P. Sedlacek, P. Schlegel, J. Arvidson, J. Toporski, A. Groll, A. Fasth, J. Winiarski, H. Ozsahin, A. Schrauder, P. Bader, M. Hoyle, M. Iacobelli, G. Dini, C. Peters on behalf of the Pediatric Disease Working Party

## 2011

### **Engineered T-lymphocytes using a novel anti-leukaemia antigen, aurora-A kinase-specific T-cell receptor gene transfer successfully displayed anti-leukaemia reactivity**

H. Fujiwara, K. Nagai, T. Ochi, J. An, T. Shirakata, J. Mineno, K. Kuzushima, H. Shiku, J. Melenhorst, E. Gostic, D. Price, M. Yasukawa (Toon, Ohtsu, Nagoya, Tsu, JP; Bethesda, US; Cardiff, UK)

**2012****TCR gene editing results in effective immunotherapy of leukaemia without the development of GvHD**

E. Provasi, P. Genovese, A. Lombardo, Z. Magnani, L. Peiqi, A. Reik, V. Chu, D. Paschon, L. Zhang, J. Kuball, B. Camisa, A. Bondanza, G. Casorati, M. Ponzoni, F. Ciceri, C. Bordignon, P. Greenberg, M. Holmes, P. Gregory, L. Naldini, C. Bonini (Milan, IT, Richmond, Seattle, US)

**2013****Long-term outcomes after autologous haematopoietic cell transplantation for multiple sclerosis: a joint study from the Center for International Blood and Marrow Research (CIBMTR) and the European Group for Blood and Marrow Transplantat**

P. Muraro\* (London, Great Britain), M. Pasquini, H. Atkins, J. Bowen, D. Farge, A. Fassas, M. Freedman, G. Georges, N. Hamerschlag, E. Havdova, T. Kozak, G. Luigi Mancardi, D. Morais, R. Nash, S. Pavletic, J. Ouyang, A. Saiz, M. Badoglio, X. Zhong, M. P. Sormani, R. Saccardi

**2014****T Cells Engineered With A Chimeric Antigen Receptor (Car) Targeting Cd19 (Ct1019 Cells) Produce Significant In Vivo Proliferation, Complete Responses And Long-term Persistence Without Gvhd In Children And Adults With Relapsed, Refractory All**

S. Grupp\* (Philadelphia, United States), N. Frey, R. Aplenc, B. Levine, S. Maude, S. Rheingold, C. Strait Barker, D. Teachey, Y. Mahnke, D. Porter, C. June

**2015****Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy)**

C. Solano\* (Valencia, Spain), F. Bonifazi, C. Wolschke, F. Patriarca, M. Pini, A. Nagler, M. Selleri, G. Messina, W. Bethge, P. Herrera Fuentes, R. Duarte, N. Cascavilla, M. Cimminiello, S. Guidi, J. Finke, A. Gallamini, C. Ferrà, J. Sierra, D. Russo, M. Petrini, G. Milone, F. Benedetti, M. Heinzelmann<sup>3</sup>, V. Liso, M. Jurado, E. M. Pogliani, F. Narni, A. Völp, G. Bandini, F. Ayuk, T. Ruutu, N. Kröger on behalf of Chronic Malignancies Working Party of the EBMT (CMWP)

**2016****Multiple inhibitory receptors are expressed on central memory and memory stem T cells infiltrating the bone marrow of AML patients relapsing after allo-HSCT**

Maddalena Noviello\* (Milan, Italy), Francesco Manfredi, Tommaso Perini, Giacomo Oliveira, Filippo Cortesi, Cristina Toffalori, Valentina Gambacorta, Raffaella Greco, Jacopo Peccatori, Attilio Bondanza, Giulia Casorati, Paolo Della-bona, Nicoletta Cieri, Fabio Ciceri, Luca Vago, Chiara Bonini

**2017****Impact of MRD before and after Allogeneic Hematopoietic Cell Transplantation (HCT) of Childhood ALL By FC and RQ-PCR: A Retrospective Study on Behalf of COG, the PBMT, the I-BFM the PDWP of the EBMT, and the Westhafen-Intercontinental-Group**

Peter Bader\* (Frankfurt, Germany), Emilia Salzmänn-Mannrique, Adriana Balduzzi, Jean-Hugues Dalle, Ann E. Woolfrey, Merav Bar, Michael R. Veneris, Michael J. Borowitz, Nirali Shah, Nathan Gossai, Peter Shaw, Allen Chen, Hermann Kreyenberg, Lucia Di Maio, Cornelia Eckert, Vincent van der Velden, Arjan Lankester, Thomas Klingebiel, Christina Peters, Stephan A. Grupp, Michael A. Pulsipher

**2018****Non-myeloablative haematopoietic stem cell transplantation versus continued disease modifying therapies (DMT) in patients with highly active relapsing remitting multiple sclerosis (RRMS)**

Richard K Burt\* (Chicago, USA), Roumen Balabanov, John A Snowden, Basil Sharrack, Maria Carolina Oliveira, Flavia Nelson, Joachim Burman

**2019****5-azacytidine (5-Aza) induction followed by allogeneic stem cell transplantation versus continuous 5-Aza in elderly MDS patients (55-70 years). A prospective randomized study (VidazaAllo Study)**

Nicolaus Kröger, Katja Sockel, Christine Wolschke, Wolfgang Bethge, Richard F. Schlenk, Dominik Wolf, Michael Stadler, Guido Kobbe, Gerald Wulf, Gesine Bug, Kerstin Schäfer-Eckart, Christoph Scheid, Florian Nolte, Jan Krönke, Matthias Stelljes, Dietrich Beelen, Marion Heinzelmann, Detlef Haase, Hannes Buchner, Gabriele Blecker, Uwe Platzbecker (Frankfurt, Germany).